All lobbying filings

EDWARDS LIFESCIENCES, LLC

EDWARDS LIFESCIENCES, LLC filed a Q3 report for EDWARDS LIFESCIENCES LLC on October 20, 2026.

Lobbying for EDWARDS LIFESCIENCES LLC

All filings by EDWARDS LIFESCIENCES, LLC · Everything EDWARDS LIFESCIENCES LLC has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$300,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) Regulatory Alignment for Predictable and Immediate Device coverage pathway Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development

Medicare/Medicaid

CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes RAPID) Heart Valve Disease Awareness National Coverage Determination for TAVR Clinical Trials Coverage with Evidence Development

Trade (domestic/foreign)

Tariffs

Bills named in this filing 2

H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.